Spdr Sp Pharmaceuticals Etf Probability Of Bankruptcy
| XPH Etf | USD 45.79 0.15 0.33% |
SPDR |
SPDR SP Pharmaceuticals ETF probability of distress Analysis
SPDR SP's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current SPDR SP Probability Of Bankruptcy | Less than 35% |
Most of SPDR SP's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SPDR SP Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of SPDR SP probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting SPDR SP odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of SPDR SP Pharmaceuticals financial health.
The market value of SPDR SP Pharmaceuticals is measured differently than its book value, which is the value of SPDR that is recorded on the company's balance sheet. Investors also form their own opinion of SPDR SP's value that differs from its market value or its book value, called intrinsic value, which is SPDR SP's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SPDR SP's market value can be influenced by many factors that don't directly affect SPDR SP's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SPDR SP's value and its price as these two are different measures arrived at by different means. Investors typically determine if SPDR SP is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SPDR SP's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, SPDR SP Pharmaceuticals has a Probability Of Bankruptcy of 35.0%. This is much higher than that of the SPDR State Street Global Advisors family and significantly higher than that of the Health category. The probability of bankruptcy for all United States etfs is notably lower than that of the firm.
SPDR Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SPDR SP's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of SPDR SP could also be used in its relative valuation, which is a method of valuing SPDR SP by comparing valuation metrics of similar companies.SPDR SP is currently under evaluation in probability of bankruptcy as compared to similar ETFs.
SPDR Fundamentals
| Price To Earning | 6.56 X | |||
| Price To Book | 1.51 X | |||
| Price To Sales | 2.83 X | |||
| Gross Profit | 2.66 M | |||
| Earnings Per Share | (11.87) X | |||
| Number Of Employees | 12 | |||
| Beta | 0.72 | |||
| Market Capitalization | 236.07 M | |||
| Total Asset | 206.63 M | |||
| One Year Return | 25.40 % | |||
| Three Year Return | 0.50 % | |||
| Five Year Return | 3.70 % | |||
| Ten Year Return | (0.20) % | |||
| Net Asset | 206.63 M | |||
| Last Dividend Paid | 0.067 | |||
| Equity Positions Weight | 99.90 % |
About SPDR SP Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SPDR SP Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SPDR SP using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SPDR SP Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether SPDR SP Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SPDR SP's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spdr Sp Pharmaceuticals Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Spdr Sp Pharmaceuticals Etf:Check out SPDR SP Piotroski F Score and SPDR SP Altman Z Score analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
The market value of SPDR SP Pharmaceuticals is measured differently than its book value, which is the value of SPDR that is recorded on the company's balance sheet. Investors also form their own opinion of SPDR SP's value that differs from its market value or its book value, called intrinsic value, which is SPDR SP's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SPDR SP's market value can be influenced by many factors that don't directly affect SPDR SP's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SPDR SP's value and its price as these two are different measures arrived at by different means. Investors typically determine if SPDR SP is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SPDR SP's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.